3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Lymphoma
3
Neoplasms
2
Rhabdoid Tumor
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Neuroepithelial
1
Neoplasms, Germ Cell and Embryonal
1
Microphthalmia, Isolated, with Coloboma 5
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Lymphoma, Follicular
1
Leukemia
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Ependymoma
1
Choroid Plexus Carcinoma
1
Central Nervous System Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
tazemetostat
2
Pemetrexed
2
Cisplatin
2
ruxolitinib
1
ribociclib
1
belinostat
1
avelumab
1
abemaciclib
1
Sirolimus
1
Rifampin
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Midazolam
1
Letrozole
1
LY3023414
1
Itraconazole
1
Immunotherapy, Adoptive
1
Immunotherapy
1
Imatinib Mesylate
1
Fulvestrant
1
Fluorodeoxyglucose F18
1
Drug Therapy
1
Doxepin
1
Biological Therapy
1
4-(3-fluoropropyl)glutamic acid
1
(4S)-4-(3-(18F)fluoropropyl)-L-glutamate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
ribociclib
×
Lymphoid
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts